Fig. 1 · Structure

Documents & Downloads

Ki8751

Cat. No. A10502 CAS 228559-41-9

VEGFR-2 inhibitor

Ki8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-free assays.

In Stock

Publications for Ki8751

1 publication citing this product

  1. Kohei Ashina, .et al. , Biochem Biophys Res Commun, 2015, Aug 21;464(2):590-5 PMID: 26163262

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In U38 glioblastoma cells, Ki8751 treatment reduced VEGFR2 phosphorylation together with AKT and PGC1α phosphorylation and increased TFAM abundance. These cellular associations support its use to investigate VEGFR2-related signaling, while leaving causal pathway order and exclusive target attribution unresolved. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
VEGFR2 IC50 0.9nM
c-Kit IC50 40nM
PDGFRα IC50 67nM
FGFR2 IC50 170nM
EGFR IC50 >10μM
HGFR IC50 >10μM
InsulinReceptor IC50 >10μM

7 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
HUVEC IC50 1 μM Antiangiogenic activity in HUVEC assessed as inhibition of cell proliferation after 72 hrs by MTT assay [PMID: 22148396]
HUVEC IC50 1.4 μM Growth inhibition of HUVEC by WST-8 assay [PMID: 24601669]

Ki8751 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Ki8751 from 2 published references. In vitro models include human U38 and U87 glioblastoma cell lines; human U38 glioblastoma cells.

Ki8751 In Vitro Studies

Ki8751 at 2.5 or 5 µM reduced growth-associated CCK-8 signals and increased Annexin V/PI-defined apoptosis in U38 and U87 glioblastoma cells over 24–72 h compared with 0.01% DMSO. These culture results do not establish clinical efficacy or a monotonic dose response. [1]

Growth and apoptosis responses in glioblastoma cells

Cell-based study · Human U38 and U87 glioblastoma cell lines [1]

Ki8751 reduced the increase in CCK-8 signal over time and increased Annexin V/PI-defined apoptosis relative to vehicle. These are cell-culture results; the two active concentrations do not establish a monotonic concentration–response relationship.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCK-8 signal normalized to optical density at time 0Relative proliferation signal Lower signal increase than vehicle at 2.5 and 5 µM across the reported time course; mean ± SEM, n = 3. No exact fold inhibition extracted.[1]
Annexin V/PI-defined apoptotic-cell percentageApoptosis Increased relative to vehicle; mean ± SEM, n = 3. No exact percentages extracted from plotted bars.[1]

Literature-Reported Treatment Conditions

Treatment concentration
2.5 and 5 µM
Exposure duration
24, 48 and 72 h
Method
Drug exposure in cell culture; CCK-8 and Annexin V-FITC/PI assays
Vehicle
0.01% DMSO
Reported limits
Figure captions report n = 3 and mean ± SEM, without specifying the biological replicate unit for these assays. Salt/hydration, lot and purity are not specified.
Methods and source locations

Compound reported in the paper: Ki8751; Compound label in the paper: Ki8751

Compound-level research evidence; no inference about the performance of an Adooq lot.

Figure 1D–G and caption; Results Sec18; Methods Sec4 and Sec6

CCK-8 signal normalized to optical density at time 0: CCK-8; signal is a metabolic readout rather than direct cell counting. — Figure 1D and caption; Methods Sec6; Results Sec18

Annexin V/PI-defined apoptotic-cell percentage: Annexin V-FITC/PI staining with flow cytometry. — Figure 1E and caption; Methods Sec6; Results Sec18

VEGFR2-associated phosphorylation changes in U38 cells

Cell-based study · Human U38 glioblastoma cells [1]

After 48 h of Ki8751 treatment, immunoblots showed reduced phosphorylated VEGFR2 relative to total VEGFR2 and lower p-AKT/AKT and p-PGC1α/PGC1α signals. TFAM abundance increased. These associated changes do not by themselves prove a causal signaling sequence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphorylated VEGFR2 relative to total VEGFR2Relative immunoblot signal Reduced with 2.5 and 5 µM Ki8751 at 48 h; no exact ratio extracted.[1]
p-AKT/AKT, p-PGC1α/PGC1α and TFAM/GAPDHRelative immunoblot signals p-AKT/AKT and p-PGC1α/PGC1α decreased; TFAM/GAPDH increased; no exact ratios extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
2.5 and 5 µM (Figure 5A treatment labels)
Exposure duration
48 h
Method
Cell-culture exposure followed by immunoblotting
Vehicle
0.01% DMSO
Reported limits
The Figure 5A caption does not specify n. Lot, purity and salt/hydration are not specified.
Methods and source locations

Compound reported in the paper: Ki8751; Compound label in the paper: Ki8751

Compound-level cellular evidence; no kinase IC50 or batch-specific activity inferred.

Figure 5A–B and caption; Results Sec23; Methods Sec4 and Sec9

Phosphorylated VEGFR2 relative to total VEGFR2: Immunoblot; total VEGFR2 and GAPDH are displayed controls. — Figure 5A (U38), caption; Methods Sec9; Results Sec23

p-AKT/AKT, p-PGC1α/PGC1α and TFAM/GAPDH: Immunoblot; AKT phosphorylation antibody targets Thr308 and PGC1α phosphorylation antibody targets S571. — Figure 5A; Methods Sec9 antibody list; Results Sec23

Ki8751 In Vivo Studies

In live zebrafish embryos, 1 µM Ki8751 suppressed calcium oscillations in endothelial tip cells budding from the dorsal aorta. Treatment began at the 22-somite stage and imaging was performed at 24–27 somite stages. The authors regarded Ki8751 as a Vegfr inhibitor in this model because possible Vegfr3 activity limits Vegfr2-specific interpretation. [2]

Suppression of endothelial calcium oscillations in zebrafish embryos

Animal study · Live Tg(fli1:Gal4FF);(UAS:GCaMP7a);(fli1:H2B-mC) zebrafish embryos; dorsal-aortic tip cells at 24–27 somite stages [2]

Ki8751 treatment from the 22-somite stage suppressed the calcium oscillations seen in budding tip cells of untreated embryos. The authors described the oscillations as abolished; low residual activity is visible in the quantification, so no exact zero or inhibition percentage is assigned.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tip-cell calcium oscillation frequency and mean ΔF/F0GCaMP7a fluorescence-based oscillatory activity Strong suppression, described as abolition in the Results; Figure 2C: n ≥ 10 cells, mean ± s.d. Tip-cell versus other-endothelial-cell comparison within treated embryos is labeled NS.[2]

Conditions shared by the study groups

Frequency
Treatment maintained during imaging
Treatment course
From 22 somite stages; 40–90 min before imaging and during imaging at 24–27 somite stages
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ki8751-treated embryos
1 µM (treatment concentration)
Untreated embryo calcium data in Figure 1; control morpholino versus vegfr2 morpholino in Figure 2D–F provides pathway context.Suppressed tip-cell calcium oscillatory activity; no exact inhibition percentage assigned.[2]
Ki8751-treated embryos
Model: Live Tg(fli1:Gal4FF);(UAS:GCaMP7a);(fli1:H2B-mC) zebrafish embryos; dorsal-aortic tip cells at 24–27 somite stages
Reported limits: Main calcium-assay vehicle and route are not specified in the read chemical-treatment description; n ≥ 10 denotes cells, not animals.
Methods and source locations

Compound reported in the paper: Ki8751; Compound label in the paper: Ki8751

Developmental zebrafish evidence; the authors treat Ki8751 as a Vegfr inhibitor because possible Vegfr3 activity limits receptor-specific attribution.

Figures 1D and 2A–F with captions; Results s2-2; Methods s4-5–s4-7

Tip-cell calcium oscillation frequency and mean ΔF/F0: Light-sheet time-lapse microscopy; fluorescence quantified in tracked endothelial cells; untreated comparison in Figure 1D. — Figure 1D; Figure 2A–C and caption; Results s2-2; Methods s4-7

Ki8751-treated embryos · Figure 2A–C; Figure 1D; Methods s4-5 and s4-7

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 228559-41-9
Applications VEGFR-2 inhibitor
Formula C24H18F3N3O4
Molecular Weight 469.4
SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=C(C=C3)NC(=O)NC4=C(C=C(C=C4)F)F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 46 mg/mL (97.99 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2.3 mg/mL
Vehicle
4% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ki8751 Research References

  1. [1] Min Guo, Junhao Zhang, Jiang Han, et al. VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis Journal of Translational Medicine (2024). PMID: 38702818 DOI: 10.1186/s12967-024-05155-1 Source material
  2. [2] Yasuhiro Yokota, Hiroyuki Nakajima, Yuki Wakayama, et al. Endothelial Ca2+ oscillations reflect VEGFR signaling-regulated angiogenic capacity in vivo eLife (2015). PMID: 26588168 DOI: 10.7554/eLife.08817 Source material

Publications

1 publication citing this product

  1. Kohei Ashina, .et al. , Biochem Biophys Res Commun, 2015, Aug 21;464(2):590-5 PMID: 26163262

Added to your cart

View Cart Checkout
Loading...